Sales of human epidermal growth factor receptor 2 (HER2)-targeting breast cancer therapies are set to grow by 3.3% per annum

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.592, 2009-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab: A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

By Garnock-Jones Karly P.   Keating Gillian M.   Scott Lesley J.  

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 215-239

Adis International

Access to resources Recommend Favorite

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

By Fabi Alessandra   Merola Roberta   Ferretti Gianluigi   Di Benedetto Anna   Antoniani Barbara   Ercolani Cristiana   Nisticò Cecilia   Papaldo Paola   Ciccarese Mariangela   Sperduti Isabella   Vici Patrizia   Marino Mirella   Gori Stefania   Botti Claudio   Malaguti Paola   Cognetti Francesco   Mottolese Marcella  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 6, 2013-04 ,pp. : 699-706

Informa Healthcare

Access to resources Recommend Favorite

The Croatian government is to pay for early-stage human epidermal growth factor receptor 2-positive breast cancer patients to receive Roche's Herceptin

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 526, 2007-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

By Reckamp Karen L.   Giaccone Giuseppe   Camidge D. Ross   Gadgeel Shirish M.   Khuri Fadlo R.   Engelman Jeff A.   Koczywas Marianna   Rajan Arun   Campbell Alicyn K.   Gernhardt Diana   Ruiz-Garcia Ana   Letrent Stephen   Liang Jane   Taylor Ian   O'Connell Joseph P.   Jänne Pasi A.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1145-1154

Blackwell Publishing

Access to resources Recommend Favorite

Cancer therapies targeted to the epidermal growth factor receptor and its family members

By Kane Susan E  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 2, 2006-02 ,pp. : 147-164

Informa Healthcare

Access to resources Recommend Favorite